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We examined mortality and recurrence of hepatocel-
lular carcinoma (HCC) among 106 transplant candi-
dates with cirrhosis and HCC who had a potential living
donor evaluated between January 1998 and February
2003 at the nine centers participating in the Adult-to-
Adult Living Donor Liver Transplantation Cohort Study
(A2ALL). Cox regression models were fitted to com-
pare time from donor evaluation and time from trans-
plant to death or HCC recurrence between 58 living
donor liver transplant (LDLT) and 34 deceased donor
liver transplant (DDLT) recipients. Mean age and calcu-
lated Model for End-Stage Liver Disease (MELD) scores
at transplant were similar between LDLT and DDLT re-
cipients (age: 55 vs. 52 years, p = 0.21; MELD: 13 vs. 15,
p = 0.08). Relative to DDLT recipients, LDLT recipients
had a shorter time from listing to transplant (mean 160
vs. 469 days, p < 0.0001) and a higher rate of HCC re-
currence within 3 years than DDLT recipients (29% vs.
0%, p = 0.002), but there was no difference in mortality
or the combined outcome of mortality or recurrence.
LDLT recipients had lower relative mortality risk than
patients who did not undergo LDLT after the center
had more experience (p = 0.03). Enthusiasm for LDLT
as HCC treatment is dampened by higher HCC recur-
rence compared to DDLT.
Key words: A2ALL, DDLT, HCC, LDLT, MELD, recur-
rence
Received 9 June 2006, revised 12 February 2007 and
accepted for publication 20 February 2007
Introduction
With careful selection criteria such as the Milan criteria,
patients transplanted for hepatocellular carcinoma (HCC),
most of whom have underlying cirrhosis, have survival
rates comparable to individuals transplanted for nonma-
lignant liver diseases (1–3). Liver transplant as a potential
cure for HCC is limited by the shortage of organs, with up to
30% of patients developing contraindications to transplan-
tation while waiting for a donor (3–5). The use of adult-to-
adult living donor liver transplantation (LDLT) may shorten
waiting time and possibly decrease waitlist mortality in pa-
tients (6,7). The extension of living liver donation to adult
recipients with HCC has understandably generated contro-
versy with respect to candidate selection, donor risk and
recipient allograft outcomes (8–10). In addition, patients
with more aggressive tumor biology, who would otherwise
drop off the waiting list due to tumor progression, might
be ‘fast-tracked’ to transplant, and this may lead to an in-
creased recurrence rate of HCC post-transplant (11).
We have analyzed clinical and tumor characteristics of 106
patients with cirrhosis and known HCC pre-transplant who
were evaluated for LDLT at the nine centers participating
in the Adult-to-Adult Living Donor Liver Transplantation Co-
hort Study (A2ALL) (12) between 1998 and 2003. About
55% of these patients went on to LDLT, while about 32%
received a deceased donor liver transplant (DDLT). These
two groups allowed us to determine if outcomes differed





Data collection and definitions
Data for this study were derived from the A2ALL Retrospective Cohort
Study and were supplemented by data from the Scientific Registry of
Transplant Recipients (SRTR) made available through a data use agreement.
The A2ALL Retrospective Cohort Study data include 819 patients who had
a potential living donor evaluated between 1/1/1998 and 2/28/2003. The
cohort included 106 patients with cirrhosis and known HCC. Study enroll-
ment was defined as the date when the first potential live donor under-
went history and physical examination for each recipient. For posttrans-
plant survival, recipients of LDLT were compared to recipients of whole or
split liver DDLT, and for overall survival, recipients of LDLT were compared
to waitlisted patients including those who subsequently underwent DDLT.
Recipients whose procedure was aborted due to recipient reasons were
included in either the LDLT (n = 2) or DDLT (n = 1) group as appropriate.
Recipients of domino transplants (n = 2) were included in DDLT group. The
model for end-stage liver disease score (MELD) was calculated as previ-
ously described (13,14) and was capped at 40. For each LDLT recipient, the
experience of the center at the time of the transplant was defined as the
case number of that LDLT at the center (i.e. the number of LDLTs previously
performed at the center plus one). The major endpoints studied were HCC
recurrence and death. The duration of follow-up since the time of trans-
plant, censored at recurrence or death, ranged from 2 to 6.5 years, median
3.7 years. Among the patients who had recurrence or died, the time from
transplant to HCC recurrence or death ranged from 0 to 3.9 years, median
10.5 months.
Preoperative radiological and laboratory studies
Tumor staging was based on the prevailing modification of the tumor node
metastasis (TNM) staging classification utilized by the Organ Procurement
and Transplantation Network (OPTN) (15). All patients had computed tomog-
raphy (CT) and/or magnetic resonance imaging (MRI) for liver tumor staging
at the time of listing, and at 3–6 month intervals until transplant.
Histopathologic studies
In the analysis of HCC characteristics in the native liver explant, tumor size
and number of tumors were recorded to determine tumor stage (T1 – T4)
according to the OPTN-modified TNM, Milan (1) and University of California
San Francisco (UCSF) criteria (3). Histologic grade based on the modified
Edmonson and Steiner criteria (16) and the presence or absence of vascular
invasion were also recorded. In patients with multiple lesions in the liver
explant, the highest tumor histologic grade was recorded.
Human subjects protection
The study was approved by the Institutional Review Boards and Privacy
Boards of the University of Michigan Data Coordinating Center and each of
the nine participating transplant centers.
Statistical analysis
Descriptive statistics (means, standard deviations and proportions) for var-
ious patient characteristics were calculated separately for patients who
eventually received an LDLT, a DDLT or no transplant. For LDLT and DDLT
recipients, explant tumor characteristics were also summarized. Statistical
differences between the LDLT and DDLT recipients’ characteristics and ex-
plant tumor characteristics were evaluated using chi-square and t-tests. A
cumulative incidence function to display the probability of receiving LDLT or
DDLT, dying on the waitlist, and remaining alive without transplant over time
since donor evaluation (17) was calculated using the SAS macro ‘comprisk’
developed at Mayo Clinic (18). Freedom from HCC recurrence, recurrence-
free survival and patient survival were estimated by Kaplan-Meier methods
and unadjusted comparisons made using the log-rank test. In the case of
complete separation (no HCC recurrence in DDLT), the effect of LDLT was
tested by Cox regression likelihood ratio test. Potential predictors of time
from transplant to death, HCC recurrence or the combined endpoint were
tested by fitting multivariable Cox regression models. Covariate effects
were reported as hazard ratios (HR) with 95% confidence intervals (CI). A
wide range of covariates were evaluated. Recipient variables included age,
gender, race, etiology of underlying liver disease, calculated MELD score
at transplant, HCC staging at enrollment, pretransplant HCC tumor ablation
and/or chemotherapy, and AFP at listing, enrollment and transplant; donor
and transplant-related variables included donor age, LDLT case number (10),
transplant era, time from listing to transplant, time from donor evaluation
to transplant, explant characteristics (stage, grade and vascular invasion),
transplant center, year of transplant and cold ischemia time. We also inves-
tigated whether there was a survival advantage for HCC candidates who
pursued LDLT, comparing the relative mortality risk for LDLT recipients to
that of waitlisted candidates including those who subsequently underwent
DDLT. A modified Cox regression model of time from first donor evaluation
to death was fitted, using the method of sequential stratification (17). Briefly,
for all LDLTs performed at a given number of days since first donor evalu-
ation, a separate comparison group (stratum) was created that included all
patients alive and without transplant prior to the time of the index LDLT(s).
The survival of the index LDLT patient(s) was compared to that of the other
patients in that stratum, and the results across all LDLT strata were pooled
in a stratified Cox regression. The variance was adjusted to account for
patients who were in the comparison groups of multiple strata. Patients
without LDLT at entry into a stratum were censored if they later received
an LDLT. All analyses were performed using SAS version 9.1 (SAS/STAT 9.1
User’s Guide, SAS Publishing, Cary, NC: SAS Institute Inc., 2004). P values
<0.05 were considered to be statistically significant.
Results
Overall outcome
The overall course of the 106 patients with HCC from
the beginning of the first potential living donor evalua-
tion is shown in Figure 1. By the end of follow-up, 10
Figure 1: Cumulative probability over time of LDLT, DDLT,
death without transplant, and remaining alive on the wait-
list, from the point of first potential living donor evaluation
(based on the cumulative incidence function).
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Table 1: HCC patient characteristics
LDLT (n = 58) DDLT (n = 34) Nontransplant (n = 14)
Characteristicsa Mean (SD) or n (%) Mean (SD) or n (%) p-Valueb Mean (SD) or n (%)
Sex 0.66
Male 45 (78%) 25 (74%) 10 (71%)
Female 13 (22%) 9 (26%) 4 (29%)
Race 0.42
White 47 (81%) 27 (79%) 11 (79%)
African American 0 (0%) 1 (3%) 2 (14%)
Other 11 (19%) 6 (18%) 1 (7%)
At listing
Tumor stage ≥ T3 27 (47%) 8 (24%) 0.067 1 (7%)
AFP (ng/mL)c 36 (27) 27 (22) 0.184 18 (12)
Tumor ablation sessions
immediately prior to or at
listing 0.78 (1.1) 0.62 (1.1) 0.53 0.33 (0.7)
≥ 1 tumor ablation
sessions immediately
prior to or at listing 24 (41%) 12 (35%) 0.94 2 (14%)
At enrollment
Age 54.5 (8.9) 51.7 (9.6) 0.16 54.7 (7.9)
Lab MELD 11.8 (4.8) 13.5 (5.3) 0.11 12.5 (4.7)
AFP (ng/mL)c 42 (34) 16 (13) 0.023 83 (70)
Tumor ablation sessions
prior to enrollment 0.86 (1.3) 0.74 (1.2) 0.64 0.42 (0.7)
≥ 1 tumor ablation
sessions prior to
enrollment 26 (45%) 14 (41%) 0.73 4 (29%)
Median interval between
listing and enrollment
(days) 37 180 0.001 57
At transplant
Age 54.6 (9) 52.1 (10) 0.21
Lab MELD 13 (5) 15 (7) 0.08
Time from listing to transplant 160 (184.9) 469 (369.8) <0.0001
Median interval between listing and 95 373 <0.0001
transplant (days)
HCV etiology of cirrhosis 35 (60%) 25 (74%) 0.20
Tumor stage ≥ T3 32 (55%) 13 (38%) 0.05
AFP (ng/mL)c 44 (36) 13 (10) 0.019
Tumor ablation sessions between 0.45 (0.6) 0.56 (1.0) 0.52
enrollment and transplant
≥1 tumor ablation sessions between enrollment 22 (38%) 11 (32%) 0.59
and transplant
Median follow-up post-LT 4.0 3.4 0.039
censored at death (years)
aNumbers of missing values for [LDLT, DDLT, nontransplant] were [0, 0, 0] for sex and race, [7–10, 6–10, 5–6] for listing variables, [0–3,
0, 0–3] for enrollment variables and [0–5, 0] for transplant variables.
bp-Values for comparison of LDLT and DDLT. Chi-square tests were used for proportions; two-sample t-tests were used for continuous
variables.
cMedian on raw scale (median absolute difference about the median), p-value from t-test on log scale.
patients had died awaiting transplant (median time from
donor evaluation to death: 9 months, range 0.3–32 months)
and four patients were still waiting for transplant (median
time from donor evaluation to last follow-up: 31 months,
range 1–69 months). Of the 92 transplanted patients, 58
received an LDLT and 34 received a DDLT. One year af-
ter donor evaluation, the cumulative probabilities of receiv-
ing an LDLT, receiving a DDLT, dying on the waiting list
and remaining alive without transplant were 0.56, 0.31,
0.05 and 0.09, respectively. Two years after donor evalua-
tion, the respective probabilities were 0.56, 0.33, 0.06 and
0.05.
Characteristics of LDLT and DDLT recipients
Characteristics of the 58 LDLT and the 34 DDLT recipients
with HCC at the time of candidate listing, at the evalua-
tion of the potential donor and at transplant are listed in
Table 1. At the time of transplant, the mean age of the re-
cipients, mean laboratory MELD score and proportion with
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Table 2: Explant tumor characteristics by transplant type
LDLT DDLT
(n = 58) (n = 34)
Mean (SD) or Mean (SD) or p
Characteristics n (%) n (%) value
Tumor stage ≥ T3 33/55 (60%) 14/31 (45%) 0.18
Tumor nodules ≤ 3 40/55 (73%) 22/30 (73%) 0.95
Diameter of largest 4.7 (2.8) 3.1 (2.0) 0.013
nodule (cm)
Largest nodule > 5 cm 17/56 (30%) 3/34 (9%) 0.058
Largest nodule > 6.5 cm 8/56 (14%) 1/34 (3%) 0.21
Bilobar HCC 23/51 (45%) 11/29 (38%) 0.53
Vascular invasion 12/55 (22%) 3/30 (10%) 0.17
Micro invasion 9/55 (16%) 3/30 (10%)
Macro invasion 3/55 (5%) 0/30 (0%)
Histologic grade > 3 7/46 (15%) 1/29 (3%) 0.26
Milan/UCSF criteria 0.12
Inside Milan 21/56 (38%) 20/34 (59%) 0.05
Outside Milan but 7/56 (13%) 4/34 (12%) 0.92
inside UCSF
Outside UCSF 28/56 (50%) 10/34 (29%) 0.055
hepatitis C virus as the underlying etiology of cirrhosis were
not significantly different between LDLT and DDLT recip-
ients, respectively. The percentage of patients with HCC
stage ≥ T3 at listing, the mean number of tumor ablation
sessions at listing, at enrollment, and between enrollment
and transplant, and the percentage of patients with at least
one tumor ablation session at listing, at enrollment, and
between enrollment and transplant were also not signifi-
cantly different between the two groups. However, mean
alpha-fetoprotein (AFP) levels at the time of enrollment
(p = 0.023) and transplant (p = 0.019), and the percent-
age of patients with HCC stage ≥ T3 at transplant were
significantly higher in the LDLT group than in the DDLT
group. LDLT recipients had a significantly shorter median
waiting time compared to DDLT recipients (95 vs. 373 days
from listing to transplant; p < 0.0001). Consequently, LDLT
recipients had a significantly longer duration of posttrans-
plant follow-up (median 4.0 vs. 3.4 years; p = 0.039).
Liver explant HCC histopathologic characteristics
HCC characteristics in the liver explants suggested more
advanced tumors among the LDLT recipients who had sig-
nificantly larger tumors (p = 0.013), a significantly lower
proportion meeting the Milan criteria (p = 0.05) and a higher
proportion outside UCSF criteria (p = 0.055). However,
there was no significant difference in bilobar HCC, vas-
cular invasion or histologic HCC grade between explants
from LDLT and DDLT recipients (Table 2).
Unadjusted posttransplant HCC recurrence
and death
After a median potential post-transplant follow-up of 4.0
years, 17 (29%) of 58 patients who received LDLT had
HCC recurrence, whereas none of the 34 patients who
had DDLT had HCC recurrence after a median follow-up of
Figure 2: Probability of freedom from HCC recurrence by time
since LDLT or DDLT. Freedom from HCC recurrence was signifi-
cantly lower in LDLT recipients compared to DDLT recipients (p =
0.002, log-rank test).
3.4 years (Figure 2). The difference in time to recurrence
between LDLT and DDLT recipients was statistically signif-
icant (p = 0.002). The probability of HCC recurrence was
0.18 at 1 year, 0.22 at 2 years, 0.29 at 3 years and 0.35
at 4 years after LDLT. Of the 17 LDLT recipients with HCC
recurrence, 11 died (five from recurrent HCC) and six were
still alive at the time of data analysis after a median of
4.2 years (range 3–7 years) after the recurrence was diag-
nosed. Among the 11 patients who died, the median time
from HCC recurrence to death was 6 months (range 1–19
months). Among the entire group of 58 LDLT recipients, 22
died (including 11 who had HCC recurrence). The causes
of death were recurrent HCC (n = 5), sepsis (n = 5), recur-
rent HCV (n = 3), respiratory failure (n = 3), suicide (n = 1),
recurrent primary liver disease not due to HCV (n = 1) and
other causes (n = 4). Twelve of 34 DDLT recipients died.
The causes of death were cardiac arrest (n = 3), stroke
(n = 1), respiratory failure (n = 1), sepsis (n = 1), recurrent
HCV (n = 2) and other causes (n = 4).
The probability of patient survival at 1, 2 and 3 years af-
ter transplantation was not significantly different for LDLT
and DDLT recipients (LDLT: 0.86, 0.76, 0.67, DDLT: 0.76,
0.74, 0.63, p = 0.91). Similarly, the probability of graft sur-
vival at 1, 2 and 3 years was not significantly different after
LDLT and DDLT (LDLT: 0.79, 0.69, 0.60, DDLT: 0.76, 0.74,
0.62, p = 0.61). The probability of recurrence-free survival
at 3 years was lower for LDLT recipients (0.58) than DDLT
recipients (0.62), but the difference was not statistically
significant (p = 0.38) (Figure 3).
HCC recurrence according to tumor stage
A slightly higher proportion of LDLT recipients (60%) had
tumors that were stage T3 or T4 at explant compared with
DDLT recipients (45%) (p = 0.18) (Table 2). However, more
advanced tumor stage did not account for the higher overall
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Figure 3: Probability of recurrence-free patient survival by
time since LDLT or DDLT. Recurrence-free survival was lower in
LDLT recipients compared to DDLT recipients, but the difference
was not significant (p = 0.38, log-rank test).
rate of HCC recurrence among LDLT recipients. No DDLT
patient, including 14 patients with stage T3 or T4, had HCC
recurrence (Table 3). The difference in time to recurrence
between LDLT and DDLT recipients was statistically signifi-
cant after adjustment for tumor stage (p = 0.0001). Among
LDLT recipients, there was no significant association be-
tween tumor stage and recurrence (p = 0.62). Of note,
one of four LDLT recipients who had no identifiable viable
tumor at explant had HCC recurrence. Among the patients
who met Milan criteria there were five recurrences among
21 LDLT and 0 recurrence among 20 DDLT recipients (Cox
regression likelihood ratio test p = 0.0195).
Predictors of HCC recurrence or death after transplant
There was no statistically significant difference between
LDLT and DDLT recipients in the risk of the combined end-
point of HCC recurrence or patient death across all tumor
stages (HR = 0.82; 95% CI 0.38–1.79; p = 0.62) after
adjusting for period of transplant (1998–2000 vs. 2001–
2003), AFP level at transplant, transplant center and recip-
ient age (Table 4). Earlier period of transplant (1998–2000
vs. 2001–2003), higher AFP level at transplant and older
recipient age at transplant were each independently as-
sociated with a significantly higher risk of the combined
outcome of HCC recurrence or patient death. Patients re-
ceiving transplants in 1998–2000 had a 4.7-fold higher risk
Table 3: HCC recurrence posttransplant by tumor stage at explant
Stage at explant LDLT DDLT Total
No HCC 1/4 0/5 1/9
T1 or T2 5/19 0/15 5/34
T3 6/17 0/6 6/23
T4 5/16 0/8 5/24
Total 17/58∗ 0/34 17/92∗
∗Two LDLT recipients were missing explant tumor stage and had
no recurrence.
of HCC recurrence or patient death than patients receiv-
ing transplants in 2001–2003 (p = 0.0006). Each unit of
natural log increase in AFP level at the time of transplant
was associated with a 57% higher risk of HCC recurrence
or patient death (p < 0.0001). The risk of HCC recurrence
or patient death varied significantly at the nine transplant
centers (p = 0.0205). Older recipient age at transplant was
associated with a 4% higher risk of HCC recurrence or pa-
tient death per year of age (p = 0.057). Although transplant
waiting time was significantly shorter in the group that re-
ceived LDLT (p < 0.0001), waiting time to transplant itself
was not predictive of HCC recurrence or post-transplant
patient death (HR=1.00; p = 0.62).
After adjusting for transplant type, AFP level at trans-
plant, transplant center, and recipient age, patients receiv-
ing transplants pre-MELD (before 2/28/2002) had a 3.1-fold
higher risk of HCC recurrence or patient death than patients
receiving transplants post-MELD (p = 0.0168). In the pre-
MELD era 54 liver transplants for HCC were performed
with 76% of the patients received an LDLT and 62% of
these LDLT recipients had an HCC outside Milan stage.
In the post-MELD era, 36 liver transplants for HCC were
performed with 58% of the patients received a DDLT and
38% of these DDLT recipients had an HCC outside Milan
stage (Table 5).
Comparison of relative mortality risk from time
of donor evaluation
A modified Cox regression model from the time of donor
evaluation to death, adjusted for candidate age and labora-
tory MELD demonstrated that relative mortality risk after
LDLT, once a center had performed at least 20 LDLT cases
overall, was significantly lower than for the comparison
group of waitlisted candidates including those who sub-
sequently underwent DDLT (HR = 0.38; 95% confidence
interval 0.16–0.91; p = 0.03). Patients with HCC who re-
ceived an LDLT performed within the first 20 cases at a
center had a similar mortality risk to those in the compari-
son group (HR = 0.95; 95% confidence interval 0.48–1.87;
p = 0.88). After adjustment for tumor stage ≥T3, similar
results were obtained (cases >20: HR = 0.39, p = 0.049;
cases ≤20: HR = 0.95, p = 0.88).
Discussion
In this study, we found that patients with HCC who un-
derwent LDLT had a significantly higher HCC recurrence
rate than their DDLT counterparts. The reasons for this dif-
ference are not completely explained by the data available
for this analysis. The organ allocation system in the United
States (both pre- and post-MELD) assigned higher priority
to patients with stage T2 (and previously T1) HCC. Patients
with HCC that exceeded these criteria were not eligible
for high priority for transplantation and were less likely to
be offered a liver from a deceased donor. For most HCC
patients meeting the criteria after the implementation of
MELD, expeditious access (within 30–90 days of listing) to
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Table 4: Cox regression model predicting HCC recurrence or death from time of transplant (n = 58 LDLT, n = 34 DDLT)
Variable p-Value Hazard ratio 95% confidence limits
LDLT vs. DDLT 0.62 0.82 0.38 1.79
Transplant year 2001–2003 0.0006 0.21 0.09 0.52
vs. 1998–2000
Log AFP at transplant <0.0001 1.57 1.28 1.92
Recipient age at transplant 0.0571 1.53 (per 10 years) 0.99 2.38
A2ALL transplant centers∗ 0.0205 Range (0.34, 4.13)
∗Hazard ratios compare each center with the A2ALL overall center average.
a deceased donor transplant rivaled access to LDLT (14).
This may have resulted in patients within criteria receiving
DDLT while patients outside of criteria received LDLT. A
DDLT offer would not be passed up if it occurred prior to
the LDLT, even if a potential live donor had already been
evaluated and accepted. Since the study spanned the pre-
MELD and post-MELD periods, this factor may have con-
tributed to LDLT recipients having more advanced tumors
than DDLT recipients. Although the percentage of patients
with tumors outside Milan criteria receiving LDLT in the
pre- and post-MELD eras were similar (25/42 vs. 10/15,
respectively), a much higher proportion of LDLT recipients
had tumors that were outside of the UCSF criteria (50% vs.
29%). However, the higher rate of HCC recurrence in the
LDLT group cannot be attributed solely to more advanced
disease, given the absence of recurrence in those with ad-
vanced HCC in the DDLT group as well as the presence of
unexpectedly high recurrence rates in patients with earlier
stage HCC who underwent LDLT. In this study, there was
no evidence of recurrence amongst the 14 DDLT patients
with T3 or T4 stage HCC on explant after a median follow-
up of 3.6 years. This remarkable lack of recurrence in these
patients who exceeded Milan and UCSF tumor stage crite-
ria is not in line with those groups’ published findings (1,3).
While it is possible that some DDLT patients may develop
HCC recurrence after a longer duration of follow-up, most
studies have shown that over 90% of patients with recur-
rent HCC are diagnosed within the first two post-transplant
years (2,5,19,20). In our study, the majority of recurrences
in the LDLT group occurred within the first year (median
time to recurrence of 10 months). Of concern was the
Table 5: Numbers of patients and posttransplant HCC recurrence
by transplant type, milan criterion, and MELD era
Tumor status at Pre-MELD Post-MELD
explant (n = 54) (n = 36)
DDLT∗
Within Milan 7 (13%) 13 (36%)
Outside Milan 6 (11%) 8 (22%)
LDLT∗∗
Within Milan 16 (30%) 5 (14%)
No. of recurrences 5 0
Outside Milan 25 (46%) 10 (28%)
No. of recurrences 7 5
∗There were no recurrences among DDLT recipients.
∗∗Two LDLT recipients were missing explant tumor status and
had no recurrence.
26% recurrence rate among LDLT patients with stage T1 or
T2 HCC disease. These study findings suggest DDLT as a
superior ‘cancer curative’ procedure, and warrants further
prospective study.
A higher rate of HCC recurrence among patients who
underwent LDLT was previously reported by one of the
A2ALL centers (11). It was hypothesized that putting pa-
tients with HCC on a fast track to transplant may not pro-
vide adequate time to assess the tumor’s biological be-
havior. Inclusion of patients with more aggressive tumors
in the LDLT group may account for the higher recurrence
rate compared to DDLT recipients who had a significantly
longer waiting time (median 95 vs. 373 days from listing
to transplant). The significantly higher AFP levels at enroll-
ment (p = 0.023) and at transplant (p = 0.019) among the
patients who underwent LDLT are evidence of more ag-
gressive tumor biology in the LDLT group overall and may
have contributed to the significantly higher (p = 0.002) HCC
recurrence rate.
Other groups have examined the outcome of LDLT in the
setting of HCC. Some have utilized LDLT for HCC only after
exhausting alternative therapies (resection, trans-arterial
chemo-embolization or radiofrequency ablation) or in pa-
tients whose synthetic dysfunction is the major indication
for transplant (21). A recent publication on LDLT recipients
with HCC divided the patients into three groups based on
pretransplant therapy: patients without any therapy (higher
MELD scores with less advanced tumors), patients with
one or two sessions of ablative treatment, and patients
with three or more sessions of treatment, reflecting dif-
ferences in the median time elapsed from the diagnosis
of HCC to LDLT (22). The patients who received one or
two sessions of ablative therapy had the best 4-year sur-
vival and the lowest recurrence rate. The importance of
at least two ablative sessions for the most effective tu-
mor ‘kill’, within a short time interval pending transplant
intervention, was associated with the best HCC-free post-
transplant patient survival and has been highlighted in two
other prospective reports (4,5). In one small study, LDLT
provided timely transplantation with much shorter wait-
ing times (24 days) than DDLT (344 days). However, as in
the current study, HCC recurrence was observed following
LDLT (2/20) but not DDLT (0/6) (7).
Another possible explanation for the higher HCC recur-
rence rate after LDLT relates to the technique of living
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donor transplant. There is typically a more meticulous dis-
section of the recipient liver prior to transplant, with preser-
vation of the native vena cava, as well as more hepatic
artery and bile duct length. It is possible that LDLT is there-
fore a less optimal cancer operation, leaving residual tu-
mor or violating tumor capsule. Greater manipulation of the
native liver may also lead to tumor embolization through
the hepatic veins. These technical requirements of the
procedure of LDLT may influence the recurrence of tu-
mor to a greater degree than that attributed to shorter
waiting time and it is hoped that the prospective study
in progress will clarify this point. However, this does not
explain the higher recurrence rate in patients with small
tumors.
Despite a higher recurrence rate, the overall mortality and
3-year recurrence-free survival rates in the LDLT group
were similar to those of the DDLT group. The role of LDLT in
HCC is reinforced by our finding of a lower relative mortality
risk compared to those who did not undergo LDLT, when
the time of potential live donor evaluation was used as the
starting time for survival analysis. However, the early sur-
vival advantage of LDLT for HCC recipients may not result
in an advantage in long term survival due to the alarming
rate of HCC recurrence observed in our study. In order to
answer the question: ‘what is the best cancer treatment
for a patient with a small HCC and a potential living donor?’,
further prospective study, in progress, is required. In the
future, application of histological and molecular tools such
as proteomics or genomics may help to select patients
with less aggressive tumor biology who have a low risk of
recurrence and may derive benefit from LDLT without the
need for a prolonged observation period with its attendant
risks.
There are several limitations to our study. The two groups
were not randomized. The comparisons in our paper be-
tween those patients who received LDLT and those who
did not receive LDLT may not necessarily be applicable to
HCC patients who do not have a potential LDLT donor. Our
finding of an increase in recurrence after LDLT may be off-
set by mortality on the waiting list for DDLT. Multivariable
analysis to test whether LDLT was associated with HCC re-
currence independent of other predictive factors was not
possible due to the absence of recurrence in the DDLT re-
cipients. Our study included early as well as later center
experiences with LDLT, which may have introduced un-
measured confounding variables resulting from changes
in clinical practice over the study period (10). The reasons
why the LDLT rate for HCC recipients was not 100% once
a living donor came forward have been detailed in another
report (23).
Finally, the lack of recurrence of HCC in the DDLT patients
was an unexpected finding. The literature would suggest
that there should have been a substantial rate of recur-
rence, particularly in those patients who exceeded T2 cri-
teria.
Acknowledgments
Presented in part at the 56th annual meeting of the American Association
for the Study of Liver Diseases, San Francisco, CA, November 2005. This
study was supported by National Institute of Diabetes & Digestive & Kidney
Diseases through cooperative agreements (listed below). Additional support
was provided by Health Resources and Services Administration (HRSA), and
the American Society of Transplant Surgeons (ASTS).
This is publication number 3 of the Adult-to-Adult Living Donor Liver Trans-
plantation Cohort Study.
The following individuals were instrumental in the planning,
conduct and/or care of patients enrolled in this study at
each of the participating institutions as follows:
Columbia University Health Sciences, New York, NY
(DK62483): PI: Jean C. Emond, MD; Co-PI: Robert
S. Brown, Jr., MD, MPH; Study Coordinators: Rudina
Odeh-Ramadan, PharmD; Taruna Chawla, MD
Northwestern University, Chicago, IL (DK62467): PI:
Michael M.I. Abecassis, MD, MBA; Co-PI: Andreas Blei,
MD; Study Coordinator: Patrice Al-Saden, RN, CTCC
University of Pennsylvania Health System, Philadelphia, PA
(DK62494): PI: Abraham Shaked, MD, PhD; Co-PI: Kim
M. Olthoff, MD; Study Coordinators: Mary Kaminski,
PA-C; Mary Shaw, RN, BBA
University of Colorado Health Sciences Center, Denver, CO
(DK62536): PI: James F. Trotter, MD; Co-PI: Igal Kam,
MD; Study Coordinators: Scott Heese, BA; Carlos Gar-
cia, BS
University of California Los Angeles, Los Angeles, CA
(DK62496): PI: Rafik Mark Ghobrial, MD, PhD; Co-PI:
Ronald W. Busuttil, MD, PhD; Study Coordinator: Lucy
Artinian, RN, MN
University of California San Francisco, San Francisco, CA
(DK62444): PI: Chris E. Freise, MD, FACS; Co-PI: Norah
A. Terrault, MD; Study Coordinator: Dulce MacLeod, RN
University of Michigan Medical Center, Ann Arbor, MI
(DK62498): PI: Robert M. Merion, MD; DCC Staff: Anna
S.F. Lok, MD; Akinlolu O. Ojo, MD, PhD; Brenda W. Gille-
spie, PhD; Douglas R. Armstrong, RN, MS; Margaret
Hill-Callahan, BS, LSW; Terese Howell, BS; Lan Tong,
MS; Tempie H. Shearon, MS; Karen A. Wisniewski,
MPH; Monique Lowe, BS
University of North Carolina, Chapel Hill, NC (DK62505): PI:
Jeffrey H. Fair, MD; Co-PI: Roshan Shrestha, MD; Study
Coordinator: Carrie A. Nielsen, MA
University of Virginia (DK62484): PI: Carl L. Berg, MD;
Co-PI: Timothy L. Pruett, MD; Study Coordinator: Jaye
Davis, RN
Medical College of Virginia Hospitals, Virginia Common-
wealth University, Richmond, VA (DK62531): PI: Robert
A. Fisher, MD, FACS; Co-PI: Mitchell L. Shiffman, MD;
Study Coordinators: Cheryl Rodgers, RN; Ede Fenick,
RN; April Ashworth, RN
National Institute of Diabetes and Digestive and Kidney
Diseases, Division of Digestive Diseases and Nutrition,
American Journal of Transplantation 2007; 7: 1601–1608 1607
Fisher et al.
Bethesda, MD: James E. Everhart, MD; Leonard B. Se-
eff, MD; Patricia R. Robuck, PhD; Jay H. Hoofnagle, MD
Supplemental data included here have been supplied by
the Arbor Research Collaborative for Health as the con-
tractor for the Scientific Registry of Transplant Recipients
(SRTR). The interpretation and reporting of these data are
the responsibility of the author(s) and in no way should be
seen as an official policy of or interpretation by the SRTR
or the U.S. Government.
References
1. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for
the treatment of small hepatocellular carcinomas in patients with
cirrhosis. N Engl J Med 1996; 334: 693–699.
2. Schwartz M. Liver transplantation for hepatocellular carcinoma.
Gastroenterology 2004; 127(Suppl. 1): S268–S276. Review. Erra-
tum in: Gastroenterology 2005; 128: 523.
3. Yao FY, Bass NM, Nikolai B et al. Liver transplantation for hepato-
cellular carcinoma: analysis of survival according to the intention-
to-treat principle and dropout from the waiting list. Liver Transpl
2002; 8: 873–883.
4. Graziadei IW, Sandmueller H, Waldenberger P et al. Chemoem-
bolization followed by liver transplantation for hepatocellular car-
cinoma impedes tumor progression while on the waiting list and
leads to excellent outcome. Liver Transpl 2003; 9: 557–563.
5. Fisher RA, Maluf D, Cotterell AH et al. Non-resective ablation
therapy for hepatocellular carcinoma: Effectiveness measured by
intention-to-treat and dropout from liver transplant waiting list. Clin
Transplant 2004; 18: 502–512.
6. Sarasin FP, Majno PE, Llovet JM et al. Living donor liver trans-
plantation for early hepatocellular carcinoma: A life-expectancy
and cost-effectiveness perspective. Hepatology 2001; 33: 1073–
1079.
7. Lo CM, Fan ST, Liu CL, Chan SC, Wong J. The role and limitation
of living donor liver transplantation for hepatocellular carcinoma.
Liver Transpl 2004; 10: 440–447.
8. Fung J, Marsh W. The quandary over liver transplantation for hep-
atocellular carcinoma: The greater sin? Liver Transpl 2002; 8: 775–
777.
9. American Society of Transplant Surgeons’ position paper on adult-
to-adult living donor liver transplantation. Liver Transpl 2000; 6:
815–817.
10. Olthoff KM, Merion RM, Ghobrial RM et al. A2ALL Study Group.
Outcomes of 385 adult-to-adult living donor liver transplant recip-
ients: A report from the A2ALL Consortium.Ann Surg 2005; 242:
314–323, discussion 323–325.
11. Kulik L, Abecassis M. Living donor liver transplantation for hepato-
cellular carcinoma. Gastroenterology 2004; 127(Suppl. 1): S277–
S282.
12. NIH. Adult to Adult living donor liver transplantation cohort study.
http://www.nih-a2all.org.2005.
13. UNOS. MELD-PELD Calculator http://www.unos.org/waitlist/-
includes local/pdfs/meld peld calculator.pdf.2005.
14. Freeman RB Jr, Wiesner RH, Roberts JP, McDiarmid S, Dykstra
DM, Merion RM. Improving liver allocation: MELD and PELD. Am
J Transplant 2004; 4(Suppl. 9): 114–131.
15. United Network for Organ Sharing. Policy 3.6. Available at
(http://www.unos.org). UNOS Proposed Modifications to Policy
3.6.4.4 Liver Transplant Candidates with Hepatocellular Carci-
noma (HCC). Public Comment Notice. March 14, 2002:32.
16. Edmonson HA, Steiner PE. Primary carcinoma of the liver: A
study of 100 cases among 48,900 necropsies. Cancer 1954; 7:
462.
17. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time
Data, 2nd Ed. Itoboken NJ: Wiley, 2002.
18. Kim WR, Therneau TM, Benson JT et al. Deaths on the liver
transplant waiting list: An analysis of competing risks. Hepatol-
ogy 2006; 43: 345–351.
19. Cillo U, Vitale A, Bassanello M et al. Liver transplantation for the
treatment of moderately or well-differentiated hepatocellular car-
cinoma. Ann Surg 2004; 239: 150–159.
20. Todo S, Furukawa H; Japanese Study Group on Organ Transplan-
tation. Living donor liver transplantation for adult patients with
hepatocellular carcinoma: Experience in Japan. Ann Surg 2004;
240: 451–459; discussion 459–461.
21. Yao FY, Hirose R, LaBerge JM et al. A prospective study on down-
staging of hepatocellular carcinoma prior to liver transplantation.
Liver Transpl 2005; 11: 1505–1514.
22. Takada Y, Ueda M, Ito T et al. Living donor liver transplantation as
a second-line therapeutic strategy for patients with hepatocellular
carcinoma. Liver Transpl 2006; [Epub ahead of print]
23. Trotter JF, Terrault NA, Kinkhabwala MM et al. Outcomes of donor
candidates evaluated for adult-to-adult living donor liver transplan-
tation. Am J Transplant 2006; (6 Suppl. 2): 116.
1608 American Journal of Transplantation 2007; 7: 1601–1608
